![]() ![]() ![]() Rugo, MD, FASCO, noted that the median time of induction chemotherapy was 4.2 months, which is not reflected in the PFS and OS data “because the timing started at randomization.” However, there was a lower incidence of treatment-related adverse effects (TRAEs) with pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy. The median estimated OS in the ITT population with pembrolizumab/olaparib was 25.1 months (95% CI, 18.3-not reached ) vs 23.4 months (95% CI, 15.8-NR) with pembrolizumab plus chemotherapy (HR, 0.95 95% CI, 0.64-1.40). In the intention-to-treat (ITT) population, results showed that the progression-free survival (PFS) per RECIST v1.1 criteria by blinded independent central review (BICR) was 5.5 months (95% CI, 4.2-8.3) with pembrolizumab/olaparib (n = 135) compared with 5.6 months (95% CI, 4.3-6.9) with pembrolizumab/chemotherapy (n = 136 HR, 0.98 95% CI, 0.72-1.33 P =. Adding olaparib (Lynparza) to pembrolizumab (Keytruda) did not lead to improvements in progression-free or overall survival (OS) compared with pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) who previously received induction pembrolizumab plus chemotherapy.įindings from the phase 2 KEYLYNK-009 study (NCT04191135) were presented during the 2023 San Antonio Breast Cancer Symposium. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |